Caleb Matthew Adler MD
Associate Professor, Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine
Join to View Full Profile
260 Stetson StCincinnati, OH 45219
Phone+1 513-558-7700
Dr. Adler is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
National Institutes of Health Clinical CenterResidency, Psychiatry, 1995 - 1998
MedStar Health Georgetown University (D.C.)Residency, Psychiatry, 1991 - 1995
Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 1991
Certifications & Licensure
OH State Medical License 1999 - 2025
DC State Medical License 1993 - 2000
American Board of Psychiatry and Neurology Psychiatry
Publications & Presentations
PubMed
- 23 citationsRandomized, placebo-controlled, adjunctive study of armodafinil for bipolar I depression: implications of novel drug design and heterogeneity of concurrent bipolar mai...Mark A. Frye, Jess Amchin, Michael Bauer, Caleb M. Adler, Ronghua Yang
International Journal of Bipolar Disorders. 2015-09-02 - 11 citationsImpulsivity predicts time to reach euthymia in adults with bipolar disorder.Erica L. Dawson, Paula K. Shear, Steven R. Howe, Caleb M. Adler, Melissa P. DelBello
Bipolar Disorders. 2014-12-01 - 9 citationsNeurofunctional changes in adolescent cannabis users with and without bipolar disorder.Samantha M. Bitter, Caleb M. Adler, James C. Eliassen, Wade Weber, Jeffrey A. Welge
Addiction. 2014-11-01
Journal Articles
- Discrete Patterns of Cortical Thickness in Youth with Bipolar Disorder Differentially Predict Treatment Response to Quetiapine but Not LithiumMelissa P DelBello, Caleb M Adler, Jeffrey R Strawn, Fabiano G Nery, Nature
Authored Content
- S114. Efficacy and Safety of Intranasal Esketamine plus an Oral Antidepressant in Elderly Patients with Treatment-Resistant DepressionApril 2018
- S114. Efficacy and Safety of Intranasal Esketamine plus an Oral Antidepressant in Elderly Patients with Treatment-Resistant DepressionApril 2018
Grant Support
- Neurofunctional And Neurochemical Markers Of Treatment Response In Bipolar ManiaNational Institute Of Mental Health2007–2011
- Neurophysiology Of Working Memory In Bipolar DisorderNational Institute Of Mental Health2003–2007
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
